Nath Bio-Genes (India) Ltd

BSE: 537291

8

total announcements

537291.BO · 15 min delayed

BSECorp ActionDividend4 Sept 2026

Nath Bio-Genes (India) Ltd

Intimation for record date

Nath Bio-Genes (India) Ltd has announced the record date for its 33rd Annual General Meeting and dividend eligibility, scheduled for September 11, 2026.

Read more →📎 1 attachment
BSECorp. Action1 Sept 2026

Nath Bio-Genes (India) Ltd

Record Date for the AGM and Dividend

Nath Bio-Genes (India) Ltd has announced the record date for its 33rd Annual General Meeting, scheduled to be held on September 24, 2026, through video conferencing. The cut-off date for determining member eligibility to vote is September 11, 2026.

Read more →📎 1 attachment
BSEOthersResults1 Sept 2026

Nath Bio-Genes (India) Ltd

Notice of Annual General Meeting and Annual Report

Nath Bio-Genes (India) Ltd has submitted its Notice of Annual General Meeting and Annual Report for the financial year 2025-26, including the adoption of financial statements, declaration of dividend, and re-appointment of a director.

Read more →📎 1 attachment
BSEAGM/EGMResults1 Sept 2026

Nath Bio-Genes (India) Ltd

Notice of Annual General Meeting and Annual Report 2025-26

Nath Bio-Genes (India) Ltd has announced its 33rd Annual General Meeting (AGM) and Annual Report for the financial year 2025-26. The AGM will be held on September 24, 2026, through video conferencing. The company will consider adopting the audited financial statements, declaring a final dividend of ₹ 2 per equity share, and re-appointing a director retiring by rotation.

Read more →📎 1 attachment
BSECompany UpdateRegulatory6 Aug 2026

Nath Bio-Genes (India) Ltd

Intimation of Initiation of Forensic Audit

Nath Bio-Genes (India) Ltd has received a communication from SEBI informing the company that a forensic audit has been initiated by SEBI to examine the company's books of account and records for the financial years 2020-21 to 2025-26.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults30 Jul 2026

Nath Bio-Genes (India) Ltd

Investor Presentation on Unaudited Financial Results as of 30th June 2026

Nath Bio-Genes (India) Ltd has announced its unaudited financial results for Q1FY27, showing a 15% increase in revenue to ₹3,228 Mn, a 13% increase in gross profit to ₹1,629 Mn, and a 17% increase in EBITDA to ₹351 Mn. The company has also reported a 12% increase in PAT to ₹327 Mn and a 12% increase in EPS to ₹17.18.

Read more →📎 1 attachment
BSECompany Update23 Jul 2026

Nath Bio-Genes (India) Ltd

Compliance Certificate under Reg 74 (5) of SEBI (DP) Regulations

Nath Bio-Genes (India) Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming that securities received for dematerialization up to 30th June 2026 have been confirmed and listed on the stock exchange.

Read more →📎 1 attachment